We are live on ! Find out more
BIOL icon

Biolase

Delisted

BIOL was delisted on the 18th of June, 2024.

34 hedge funds and large institutions have $48.1M invested in Biolase in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

1.26% less ownership

Funds ownership: 48.82% → 47.56% (-1.3%)

6% less funds holding

Funds holding: 36 → 34 (-2)

22% less capital inflows, than outflows

Capital inflows: $5.14M | Capital outflows: $6.6M

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
34
Holders Change
-2
Holders Change %
-5.56%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
8
Reduced
8
Closed
7
Calls
$82​K
Puts
–
Net Calls
+$82​K
Net Calls Change
+$82​K

BIOL Hedge Fund Activity: Q2 2015 in Review

34 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Biolase (BIOL) for Q2 2015, worth a combined $48.1M — down 10% from $53.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BIOL and 5 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Boston Partners, opening a new position worth an estimated $2.78M. The largest seller was Camber Capital Management, cutting an estimated $4M.

  • 34 institutional investors held Biolase (BIOL) as of Q2 2015, down from 36 in Q1 2015.
  • Funds reported $48.1M of Biolase stock for Q2 2015, down 10% quarter-over-quarter.
  • 5 funds opened new Biolase positions in Q2 2015 and 7 closed out, a net change of -2 holders.
  • The largest Biolase buyer in Q2 2015 was Boston Partners, an estimated $2.78M added.
  • The largest Biolase seller in Q2 2015 was Camber Capital Management, an estimated $4M sold.

Based on aggregated 13F filings for Q2 2015.